A Study to Evaluate the Anti-inflammatory Effects of Solithromycin in Chronic Obstructive Pulmonary Disease
Status:
Terminated
Trial end date:
2017-01-05
Target enrollment:
Participant gender:
Summary
This study examines the potential benefit of a new antibiotic, Solithromycin, for the
long-term treatment of Chronic Obstructive Pulmonary Disease (COPD). Solithromycin is
hypothesised to work by reducing inflammation in the lungs of patients with COPD. Stable COPD
patients will receive treatment with solithromycin for 28 days and comparisons will be made
between any effects observed with Solithromycin and a placebo. This will include any changes
in inflammatory proteins, lung function and reported symptoms.